Cutaneous Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma
Conditions
Keywords
Vaccine, Personalized, Immunotherapy, Solid Tumor, Personal, Skin, Lung, Cancer, Bladder, Kidney, Melanoma, Carcinoma
Brief summary
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's personalized vaccine in the form of synthetic long peptides (SLPs).
Detailed description
This first-in-human study of GEN-009 will be conducted in two parts in adult patients with cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, or renal cell carcinoma (Part B only). In Part A, the safety and immunogenicity of single-agent GEN-009 will be evaluated in patients with the above-noted tumor types who have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy) and have no evidence of disease (NED) at the time of initiating vaccination with GEN-009. In Part B, up to 15 patients in each disease cohort will be enrolled and evaluated for safety, immunogenicity, and preliminary antitumor activity of GEN-009. Patients in Part B will receive GEN-009 at the schedule selected in Part A, in combination with a PD-1 inhibitor therapy (nivolumab or pembrolizumab) at the approved dose and schedule per the United States Package Insert (USPI). In addition, up to 15 patients who enroll in one of the Part B disease-specific cohorts but whose disease progresses during the screening period therapy may be enrolled into a separate relapsed/refractory disease cohort.
Interventions
BIOLOGICALGEN-009 Adjuvanted Vaccine
GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
DRUGNivolumab
Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
DRUGPembrolizumab
Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Sponsors
Genocea Biosciences, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: * Diagnosis of 1 of the following tumor types: 1. Melanoma (cutaneous). 2. NSCLC. 3. SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal). 4. Urothelial carcinoma. 5. Renal cell carcinoma (Part B only). * Understand the study, be willing to comply with all study procedures and sign the informed consent * Adequate tumor tissue available * ECOG performance status of 0 or 1 * Negative pregnancy test (females of childbearing potential) * Agree to use of contraception during the study until at least 90 days after final GEN-009 dose * Adequate hematologic, liver, and kidney function Part A-specific Inclusion: * Have completed or will complete treatment for their disease with curative intent * Have no evidence of disease Part B-specific Inclusion: * Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below: 1. NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel 2. SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) ≥ 1. 3. Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab. 4. Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who: 1. Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS ≥ 10, or are not eligible for any platinum-containing chemotherapy, OR 2. Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 5. Renal Cell Carcinoma: 1. Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR 2. Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab. * Disease assessment by CT or MRI * Have at least 1 lesion that is measureable by RECIST 1.1 * Agree to a tumor biopsy 50 days after first GEN-009 vaccination * Participants with hypothyroidism must be on thyroid replacement treatment General
Exclusion criteria
* Received a live vaccine ≤ 28 days, or a non-live vaccine ≤ 14 days, prior to the first dose of GEN-009 * Acute or chronic skin disorders that would interfere with injection * Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable * Allergy to the vaccine adjuvant Hiltonol (poly-ICLC) * Active hepatitis B or hepatitis C infection * HIV Positive * History of clinically significant cardiac condition * History of leptomeningeal carcinomatosis * Had clinically active immune-mediated disease within 5 years * Received a prior allogeneic stem cell transplant * Has primary immune deficiency * Received a prior solid organ transplant * Has malignant disease, other than the tumor types being treated in this study * Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until ≥ 90 days from last dose of GEN-009 * Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study * Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis Part A-specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | 1.5 years after first GEN-009 vaccination | Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 |
| T-cell responses to GEN-009 adjuvanted vaccine | 1.5 years after first GEN-009 vaccination | Immunogenicity based on T-cell responses to GEN-009 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antitumor activity of GEN-009 in Part B | 48 weeks after first GEN-009 vaccination | Evaluation conducted based on RECIST v1.1 (and immune-related RECIST \[irRECIST\], where appropriate) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Long-term clinical outcomes of Part A participants | 1.5 years after first GEN-009 vaccination | Disease recurrence |
| Tumor-infiltrating T cells after vaccination with GEN-009 | 1 year after first GEN-009 vaccination | Will be examined in tumor biopsies |
| Additional cellular responses after vaccination with GEN-009 | 1 year after first GEN-009 vaccination | Cytokine secretion |
| Phenotype of circulating immune cells after vaccination with GEN-009 | 1 year after first GEN-009 vaccination | Measured by flow cytometry |
Countries
United States
Outcome results
None listed